LFCM
MRKR icon

Long Focus Capital Management’s Marker Therapeutics MRKR Stock Holding History

Long Focus Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-146,100
Closed -$104K – 117
2023
Q1 		$104K Hold
146,100
– – 0.01% 110
2022
Q4 		$388K Hold
146,100
– – 0.03% 93
2022
Q3 		$539K Sell
146,100
-97,486
-40% -$358K 0.05% 85
2022
Q2 		$804K Hold
243,586
– – 0.08% 81
2022
Q1 		$1.07M Buy
243,586
+120,260
+98% +$687K 0.14% 75
2021
Q4 		$1.17M Buy
+123,326
New +$1.64M 0.16% 70

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Long Focus Capital Management's MRKR Position: Q2 2023 in Review

Long Focus Capital Management sold out of Marker Therapeutics (MRKR) in Q2 2023, closing a stake of 146,100 shares — an estimated $104K sold.

Long Focus Capital Management first reported a position in MRKR in Q4 2021 and held it in 6 quarters. The position peaked at $1.17M in Q4 2021. 29 funds tracked by Wall St. Rank hold MRKR as of Q2 2023.

  • Long Focus Capital Management reported no remaining Marker Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Long Focus Capital Management sold 146,100 Marker Therapeutics shares in Q2 2023, an estimated $104K.
  • Long Focus Capital Management first reported a position in Marker Therapeutics in Q4 2021 and held it in 6 quarters.
  • Long Focus Capital Management's Marker Therapeutics position peaked at $1.17M in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2023.

Based on Long Focus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.